239 related articles for article (PubMed ID: 17650451)
1. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.
Davies FE; Wu P; Jenner M; Srikanth M; Saso R; Morgan GJ
Haematologica; 2007 Aug; 92(8):1149-50. PubMed ID: 17650451
[TBL] [Abstract][Full Text] [Related]
2. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
Kropff M; Liebisch P; Knop S; Weisel K; Wand H; Gann CN; Berdel WE; Einsele H;
Ann Hematol; 2009 Nov; 88(11):1125-30. PubMed ID: 19274460
[TBL] [Abstract][Full Text] [Related]
3. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
4. Current status of bortezomib in the treatment of multiple myeloma.
Cavo M
Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma].
Wang LX; Lu H; Shen WY; Qian SX; Qiu HX; Wu HX; Zhang JF; Wu YJ; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):943-5. PubMed ID: 18718096
[TBL] [Abstract][Full Text] [Related]
6. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Harrison SJ; Quach H; Link E; Seymour JF; Ritchie DS; Ruell S; Dean J; Januszewicz H; Johnstone R; Neeson P; Dickinson M; Nichols J; Prince HM
Blood; 2011 Dec; 118(24):6274-83. PubMed ID: 21911830
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Caballero-Velázquez T; López-Corral L; Encinas C; Castilla-Llorente C; Martino R; Rosiñol L; Sampol A; Caballero D; Serrano D; Heras I; San Miguel J; Pérez-Simón JA
Br J Haematol; 2013 Aug; 162(4):474-82. PubMed ID: 23772672
[TBL] [Abstract][Full Text] [Related]
8. [Effect of Velcade combined with Dexamethasone on multiple myeloma].
He Q; Zhao X; He Y; Tan D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):864-7. PubMed ID: 20818081
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Knopf KB; Duh MS; Lafeuille MH; Gravel J; Lefebvre P; Niculescu L; Ba-Mancini A; Ma E; Shi H; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):380-8. PubMed ID: 25023616
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
13. [Velcade in multiple myeloma].
Votiakova OM; Osmanov DSh; Demina EA; Falaleeva NA; Bialik TE; Riabukhina IuE; Timofeeva OL; Gromova EG; Kupryshina NA; Kochergina NV
Ter Arkh; 2007; 79(7):70-3. PubMed ID: 17802795
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC
Br J Haematol; 2004 Oct; 127(2):165-72. PubMed ID: 15461622
[TBL] [Abstract][Full Text] [Related]
15. Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
Mangiacavalli S; Pochintesta L; Pascutto C; Cocito F; Pompa A; Cazzola M; Corso A
Am J Hematol; 2013 Feb; 88(2):102-6. PubMed ID: 23224960
[TBL] [Abstract][Full Text] [Related]
16. Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.
Ciolli S; Leoni F; Gigli F; Rigacci L; Bosi A
Leuk Lymphoma; 2006 Jan; 47(1):171-3. PubMed ID: 16321846
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy.
Howman R; Thakerer A; Pitman M; Ding N; Thompson PA; Khot A; Harrison SJ
Leuk Lymphoma; 2010 Dec; 51(12):2299-302. PubMed ID: 20929329
[No Abstract] [Full Text] [Related]
18. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; San-Miguel JF; Bladé J; Boccadoro M; Cavenagh J; Dalton WS; Boral AL; Esseltine DL; Porter JB; Schenkein D; Anderson KC;
N Engl J Med; 2005 Jun; 352(24):2487-98. PubMed ID: 15958804
[TBL] [Abstract][Full Text] [Related]
19. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
